Nxera Pharma Co (Nxera Pharma Co) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co 5-Year EBITDA Growth Rate?

Nxera Pharma Co's EBITDA per Share for the three months ended in Mar. 2024 was $-0.12.

During the past 12 months, Nxera Pharma Co's average EBITDA Per Share Growth Rate was -256.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nxera Pharma Co was 131.50% per year. The lowest was -39.80% per year. And the median was 26.20% per year.

Competitive Comparison of Nxera Pharma Co's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Nxera Pharma Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's 5-Year EBITDA Growth Rate falls into.

Nxera Pharma Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nxera Pharma Co (OTCPK:SOLTF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Nxera Pharma Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.